SCHEMBL24089960

SCHEMBL24089960

CCc1ccc2nc(Nc3ccc(CN4CCC4)cc3)n(-c3ccccc3)c(=O)c2c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPC5 Q9UL62 2/20 0.43
IDO1 P14902 1/20 0.43
TDO2 P48775 1/20 0.43
IDO2 Q6ZQW0 1/20 0.43
ACP1 P24666 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM1A O60341 1/20 0.40
ACHE P22303 2/20 0.40
APP P05067 1/20 0.40
BACE1 P56817 1/20 0.40
AVPR1B P47901 2/20 0.39
HSD17B10 Q99714 1/20 0.39
KDM4E B2RXH2 1/20 0.39
JAK2 O60674 1/20 0.38
SYK P43405 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23065073 0.89 ACP1 (0.48) IDO1TDO2IDO2ACP1KDM1A
SCHEMBL23065101 0.88 MEN1 (0.48) IDO1TDO2IDO2ACP1MEN1
SCHEMBL24090008 0.88 ALDH1A1 (0.50) ACP1MEN1KMT2AMAPTALDH1A1
SCHEMBL24090111 0.88 KDM1A (0.42) IDO1TDO2IDO2ACP1MEN1
SCHEMBL24090104 0.88 USP2 (0.44) MAPT
SCHEMBL24089982 0.87 JUN (0.45) MAPT
SCHEMBL24089994 0.87 MAP3K7 (0.49) ACP1MEN1KMT2AALDH1A1HSD17B10
SCHEMBL23065072 0.86 ACP1 (0.52) ACP1MEN1KMT2AALDH1A1ACHE
SCHEMBL29623202 0.86 ACP1 (0.52) ACP1MEN1KMT2AALDH1A1ACHE
SCHEMBL24089963 0.86 MAPT (0.43) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL TRPC5 3036/4885IDO1 386/4885TDO2 2059/4885
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, SLC26A3 TRPC5 2773/4885IDO1 592/4885TDO2 1774/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 TRPC5 2773/4885IDO1 592/4885TDO2 1774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.